Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Reduced-Intensity Therapy with Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Final Results of a Phase II Trial

Ryan D. Cassaday, Kelsey-Leigh A. Garcia, Olga Sala-Torra, Philip A. Stevenson, Christen H. Martino, Yajuan J. Liu, Min Fang, Mary-Elizabeth M. Percival, Anna B. Halpern, Pamela S. Becker, Vivian G. Oehler, Andrei R Shustov, Jason P. Cooper, Johnnie J. Orozco, Paul C. Hendrie, Roland B. Walter, Jerry P. Radich, Lorinda A. Soma, Elihu H. Estey

Blood (2021) 138 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2021-145648

Published: 2021

Journal Articles

Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis

Kelsey-Leigh A Garcia, Philip A. Stevenson, MS, Sindhu Cherian, MD, Christen N. Martino, NP, Andrei R Shustov, MD, Pamela S. Becker, MDPhD, Mary-Beth M. Percival, MD, Vivian G. Oehler, MD, Anna B. Halpern, MD, Roland P Walter, MDPhD, Johnnie Orozco, MD, Colin D. Godwin, MDMPhil, Sioban Keel, MD, Elihu H. Estey, MD, Ryan D. Cassaday, MD

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-137780

Published: 2020

Journal Articles

Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis

Andrew J. Cowan, MD, Philip A. Stevenson, MS, Noam Kopmar, MD, Edward N. Libby, III, MD, Pamela S. Becker, MD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Damian J. Green, MD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD

Blood (2018) 132 (Supplement 1): 198.

https://doi.org/10.1182/blood-2018-198

Published: 2018

Journal Articles

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

Ryan D. Cassaday, MD, Lorinda A. Soma, MD, Olga Sala-Torra, MD, Philip A. Stevenson, MS, Mary-Elizabeth M. Percival, MD, Vivian G. Oehler, MD, Andrei R. Shustov, MD, Pamela S. Becker, MD, Anna B. Halpern, MD, Kelsey-Leigh Garcia, Christen N. Heye, ARNP, Jerald P. Radich, MD, Elihu H. Estey, MD

Blood (2018) 132 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2018-99-110661

Published: 2018

Journal Articles

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Victor A. Chow, MD, Joseph Rajendren, MD, Andrew Shields, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Ryan D. Cassaday, MD, Andrew J. Cowan, MD, Paul J. Martin, MD, Leona Holmberg, MD PhD, Ted Gooley, PhD, Philip A. Stevenson, MS, John M. Pagel, MD PhD, Damian J. Green, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2018.

https://doi.org/10.1182/blood.V130.Suppl_1.2018.2018

Published: 2017

Journal Articles

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

Camille E. Puronen, MD, Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Brenda M. Sandmaier, MD, Mary E. Flowers, MD, Damian J. Green, MD, David G. Maloney, MD PhD, Rainer F. Storb, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 4559.

https://doi.org/10.1182/blood.V130.Suppl_1.4559.4559

Published: 2017

Journal Articles

Time to Minimal Residual Disease (MRD) Negativity Is Independently Predictive of Outcome in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD

Ryan D. Cassaday, MD, Philip A. Stevenson, Brent L. Wood, MD PhD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Brenda M. Sandmaier, MD, Jerald P. Radich, Andrei R. Shustov, MD

Blood (2015) 126 (23): 2498.

https://doi.org/10.1182/blood.V126.23.2498.2498

Published: 2015

Journal Articles

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Solomon A. Graf, MD, Philip A. Stevenson, MS, Leona A. Holmberg, MD PhD, Brian G. Till, MD, Oliver W. Press, MD PhD, Thomas R. Chauncey, MD PhD, Stephen D. Smith, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, MD, William I. Bensinger, MD, John M. Pagel, MD PhD, David G Maloney, MDPhD, Yi Zhou, MD PhD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3985.

https://doi.org/10.1182/blood.V124.21.3985.3985

Published: 2014

Journal Articles

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Theodore A. Gooley, PhD, Thomas Chauncey, MD PhD, John Pagel, MD PhD, Brian G. Till, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, William I. Bensinger, MD, Leona Holmberg, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Stephen D. Smith, MD, Edward N. Libby, MD, David G Maloney, MDPhD, Lorinda A. Soma, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3967.

https://doi.org/10.1182/blood.V124.21.3967.3967

Published: 2014

Journal Articles

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Bronwyn H. Bryant, MD, Cecilia Yeung, MD, Brian G. Till, MD, Stephen D. Smith, MD, Edward N. Libby, MD, Andrei R. Shustov, MD, John M. Pagel, MD PhD, Damian J. Green, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Min Fang, MD PhD, Leona Holmberg, MD PhD, William I. Bensinger, MD, David G Maloney, MDPhD, Ajay K. Gopal, MD, Oliver W. Press, MD PhD

Blood (2014) 124 (21): 1731.

https://doi.org/10.1182/blood.V124.21.1731.1731

Published: 2014

NARROW

Reduced-Intensity Therapy with Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Final Results of a Phase II Trial

Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis

Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

Time to Minimal Residual Disease (MRD) Negativity Is Independently Predictive of Outcome in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only